Tag - Zylö Therapeutics

Zylö and Amifar Laboratorios Forge Broad-Ranging Partnership

Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into a broad-ranging agreement with Amifar Laboratorios Spain to supply Z-pods to further enhance Amifar’s new line of advanced cosmetics. Amifar and Zylö have initiated a product development collaboration beginning with two actives and have plans to expand the list of actives over time. Read more >>

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a Joint Venture with Zylo Therapeutics. This Joint Venture will utilize Zylo’s innovative sustained release topical delivery system that was originally developed at Albert Einstein College of Medicine using Silo Pharma’s expertise in the use of psychedelics. Read more >>

Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>

Grapefruit USA, Inc. Commences Production of Its Patented Disruptive Time Release Hourglass(TM) THC+CBD Delivery Cream

Grapefruit USA, Inc., a fully licensed California based cannabis company, is announcing today that it has commenced production of the Hourglass™ time release THC+CBD delivery cream at its manufacturing facility in the Coachillin Canna-Business Park in Desert Hot Springs, California, pursuant to its Exclusive License and Supply Agreement with Zylö Therapeutics Inc. Read more >>

Zylö and Grapefruit Forge Partnership That Promises to Disrupt the Topical Cannabis Market

Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into an exclusive agreement with Grapefruit USA, Inc. to supply its Z-pod™ system as the technological underpinning of Grapefruit’s Hourglass™ time-release cannabinoid topical cream. Read more >>